137862-53-4 + 149709-62-6 = 137862-53-4 + 936623-90-4 + 149709-62-6 反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Acetone,Water; 1 H,25 - 35 °C 标题:Preparation Of Solid State Forms Of Trisodium Salt Of Valsartan/sacubitril Complex And Sacubitril Sodium 参考文献:World Intellectual Property Organization]
42882-31-5 + 137862-53-4 + 149709-62-6 = 137862-53-4 + 936623-90-4 + 149709-62-6 反应条件:1.1 Solvents: Acetone; 10 Min,Rt1.2 Reagents: Sodium Hydroxide Solvents: Water; 10 - 20 °C; 1 H,10 - 20 °C 标题:Preparation Of Sacubitril And Salt Thereof And Novel Compounds Used In The Process 参考文献:World Intellectual Property Organization]
391230-93-6 + 149690-05-1 = 137862-53-4 + 936623-90-4 + 149709-62-6 反应条件:1.1 Solvents: Acetone,Water; 10 Min,Rt; 30 Min,Rt -> 80 °C 标题:Novel Crystal Forms Of Entresto: A Supramolecular Complex Of Trisodium Sacubitril/valsartan Hemi-Pentahydrate 作者:Shaikh,Tabrez R.; George,Christy P.; Bhukya,Priyanka; Shelke,Nikita; Pawar,Komal; Et Al 参考文献:Crystengcomm 日期:2022 卷标:24(42) 页码:7387-7393]
N-[(2'-(1-Triphenylmethyl-Tetrazol-5-yl)Biphenyl-4-yl)Methyl]-N-Valeroyl-(L)-Valine Benzyl Ester置于钯 异丙醇,水,氢氧化钾,甲苯,乙酸乙酯,Raw Product,环己烷体系中,用 甲醇 用作溶剂,化学反应 26.0H,以yielded 250 G (67%) Of Valsartan的收率获得缬沙坦 参考文献:Method Of Preparation Of N-(1-Oxopentyl)-N-[[2'-(1H-Tetrazol-5-Y1) [1,1'-Biphenyl]-4-Y1]Methyl]-L-Valine (Valsartan) 标题:Method Of Preparation Of N-(1-Oxopentyl)-N-[[2'-(1H-Tetrazol-5-Y1) [1,1'-Biphenyl]-4-Y1]Methyl]-L-Valine (Valsartan) 摘要:从起始的4-溴甲基-2'-(1-三苯甲基四唑-5-基)联苯开始,通过与l-缬氨酸苄酯反应得到式7的n-[(2'-(1-三苯甲基四唑-5-基)联苯-4-基)甲基]-(L)-缬氨酸苄酯,然后通过与戊酰氯反应并去除保护基将其转化为式i的缬沙坦.该方法包括使用盐酸将在第一阶段得到的式7的n-[(2'-(1-三苯甲基四唑-5-基)联苯-4-基)甲基]-(L)-缬氨酸苄酯转化为式iii的n-[(2'-(1-三苯甲基四唑-5-基)联苯-4-基)甲基]-(L)-缬氨酸苄酯盐酸盐,可选择性地重结晶.
专利号:US-2021107859-A1 优先权日:2018-04-06 标题 :A process for the synthesis of carbon labeled organic compounds 发明人:AUDISIO DAVIDE; CANTAT THIBAULT; DESTRO GIANLUCA 权利人:COMMISSARIAT ENERGIE ATOMIQUE 摘要:A process for the synthesis of a carbon labeled organic compound containing a carbon labeled carboxyl group is described. A method of using carbon labeled organic compounds containing a carbon labeled carboxyl group according to the present disclosure; a process for manufacturing labeled pharmaceuticals and agrochemicals comprising synthesis of carbon labeled organic compounds containing a carbon labeled carboxyl group according to the present disclosure; and a process for producing tracers comprising synthesis of carbon labeled organic compounds containing a carbon labeled carboxyl group according to the present disclosure are also described.
专利号:US-10925977-B2 优先权日:2006-10-05 标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications 发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S 权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS 摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.
专利号:US-10973847-B2 优先权日:2017-06-30 标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof 发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R 权利人:MASSACHUSETTS INST TECHNOLOGY 摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.
专利号:US-2008214637-A1 优先权日:2004-11-11 标题 :Process for the Synthesis of Tetrazoles 发明人:ANTONCIC LJUBOMIR; LUDESCHER JOHANNES 权利人:LEK PHARMACEUTICALS 摘要:A process for the synthesis of tetrazol derivative has been developed which starts from a tetrazole derivative where acidic hydrogen atom has been replaced by a protecting group and the deprotection is performed with a catalytic amount of organic acid and can proceed in an aqueous solvent.
专利号:US-10005720-B2 优先权日:2013-04-05 标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same 发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L 权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL 摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.
专利号:US-6271375-B1 优先权日:1997-06-30 标 题 :Ortho-metalation process for the synthesis of 2-substituted-1-(tetrazol-5-yl)benzenes 发明人:VILLA MARCO; ALLEGRINI PIETRO; ARRIGHI KATIUSCIA; PAIOCCHI MAURIZIO 权利人:ZAMBON SPA 摘要:A process of direct metalation of phenyltetrazoles useful for preparing compounds of formula (II) intermediates for the synthesis of angiotensin II antagonists is described.
1: Hasabo EA, Isik B, Elgadi A, Yacoub MS, Bakr MS, Eljack MMF, Sultan S, Caliskan K, Soliman O. A Systematic Review and Meta-Analysis of an Angiotensin Receptor-Neprilysin Inhibitor in Patients Using a Durable Left Ventricular Assist Device. J Clin Med. 2024 Dec 20;13(24):7789. doi: 10.3390/jcm13247789. 13(24):7659. doi: 10.3390/jcm13247659. 65(3):E395-E402. doi: 10.15167/2421-4248/jpmh2024.65.3.3305. 4: Abumayyaleh M, Krack C, Demmer J, Pilsinger C, Schupp T, Behnes M, Sattler K, El-Battrawy I, Hamdani N, Akin I. Sex differences and clinical outcomes, including ventricular tachyarrhythmias, of patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. Front Cardiovasc Med. 2024 Dec 19;11:1503414. doi: 10.3389/fcvm.2024.1503414. 5: Perry B, Jakab J, Robinson B, McElhaney E, Fallon J, Geyer K. Implementation of an adherence pharmacy referral protocol for patients taking sacubitril/valsartan. J Manag Care Spec Pharm. 2025 Jan;31(1):83-87. doi: 10.18553/jmcp.2025.31.1.83.
合成参考文献
参考文献:10.1038/sj.jhh.1001963 摘要:Arosio E, De Marchi S, Prior M, Rigoni A, Lechi A. Haemodynamic effects of AT1 inhibition and Ca2+-channel blockade in hypertensive patients during isometric stress. J Hum Hypertens. 2006 Mar;20(3):201–5. doi: 10.1038/sj.jhh.1001963. 参考文献:10.1097/mbp.0b013e32834944e9 摘要:Duprez DA, Weintraub HS, Cushman WC, Purkayastha D, Zappe D, Samuel R, Izzo JL. Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. Blood Press Monit. 2011 Aug;16(4):186–96. doi: 10.1097/mbp.0b013e32834944e9. 参考文献:10.4061/2011/132405 摘要:Tedla FM, Brar A, Browne R, Brown C. Hypertension in Chronic Kidney Disease: Navigating the Evidence. International Journal of Hypertension. 2011;2011():1–9. doi: 10.4061/2011/132405. 参考文献:10.4061/2011/346985 摘要:Essick EE, Sam F. Cardiac Hypertrophy and Fibrosis in the Metabolic Syndrome: A Role for Aldosterone and the Mineralocorticoid Receptor. International Journal of Hypertension. 2011;2011():1–12. doi: 10.4061/2011/346985. 参考文献:10.4061/2011/284823 摘要:Kinouchi K, Ichihara A, Bokuda K, Kurosawa H, Itoh H. Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial). International Journal of Hypertension. 2011;2011():1–11. doi: 10.4061/2011/284823.